Niagen Bioscience (NASDAQ:NAGE) Given Buy Rating at Canaccord Genuity Group

Canaccord Genuity Group reiterated their buy rating on shares of Niagen Bioscience (NASDAQ:NAGE) in a research note published on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a $13.00 price objective on the stock.

NAGE has been the subject of a number of other reports. Wall Street Zen raised shares of Niagen Bioscience from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings restated a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $16.00.

Niagen Bioscience Price Performance

NAGE opened at $4.41 on Tuesday. Niagen Bioscience has a 1 year low of $4.16 and a 1 year high of $14.69. The company has a market capitalization of $353.15 million, a price-to-earnings ratio of 22.05 and a beta of 2.11. The firm’s fifty day moving average price is $5.15 and its two-hundred day moving average price is $6.50.

Hedge Funds Weigh In On Niagen Bioscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Precision Wealth Strategies LLC purchased a new stake in Niagen Bioscience during the third quarter worth about $1,527,000. Hillsdale Investment Management Inc. purchased a new position in Niagen Bioscience in the third quarter valued at about $2,988,000. Navellier & Associates Inc. purchased a new position in Niagen Bioscience in the third quarter valued at about $1,768,000. BSW Wealth Partners bought a new position in shares of Niagen Bioscience during the 3rd quarter valued at approximately $793,000. Finally, Gamco Investors INC. ET AL bought a new position in shares of Niagen Bioscience during the 3rd quarter valued at approximately $1,170,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services.